Detail akcie Mode online

Business Summary: Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Sygnis SA revenues increased 31% to PLN9.8M. Net income applicable to common stockholders totaled PLN2.6M vs. loss of PLN11.3M. Revenues reflect Sales of Products increase from PLN1.4M to PLN8.1M. Net Income reflects FV Adjustments of Financial Investments decrease from PLN7.6M (expense) to PLN0K, Other Operating Expense decrease of 96% to PLN106K (expense), Salaries decrease of 43% to PLN2.1M (expense).